With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case
The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.
Many fear the push to put more people on the new brand-name drug before Truvada goes generic this year.
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
Pre-exposure prophylaxis (PrEP) is a vital part of ending HIV, but ads targeting people to join lawsuits are planting needless fears in patients, three leading HIV specialists write.
The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.
Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results
Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.
But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.